Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure

Division of Cardiology, Stanford University Medical Center, California 94305.

The cardiac release and total body and renal clearances and the hemodynamic, renal and endocrine effects of increasing doses of atrial natriuretic peptide were investigated in 12 patients with severe chronic congestive heart failure. Immunoreactive arterial plasma levels of atrial natriuretic peptide were 10-fold higher than normal and there was no correlation between aortic atrial natriuretic peptide and cardiac filling pressures. The heart released atrial natriuretic peptide into the coronary sinus. The kidney, though a major clearance site, accounted for only 33% of the total body clearance. Administration of 0.3 micrograms/kg per min atrial natriuretic peptide produced significant changes in heart rate (95 +/- 4 to 85 +/- 4 beats/min) and mean arterial (92 +/- 8 to 77 +/- 9 mm Hg), right atrial (13 +/- 3 to 8 +/- 2 mm Hg) and mean pulmonary artery occluded (27 +/- 3 to 14 +/- 3 mm Hg) pressures. Atrial natriuretic peptide increased cardiac index (2.25 +/- 0.18 to 2.83 +/- 0.3 liters/min per m2) and stroke work index (21 +/- 1.5 to 29 +/- 3.4 g/m2), whereas systemic vascular resistance (1,424 +/- 139 to 1,033 +/- 97 dynes.s.cm(-5)) decreased. Infusion of 0.1 microgram/kg per min atrial natriuretic peptide increased urinary flow 128%, fractional excretion of sodium 133% and fractional excretion of potassium 35%. The filtration fraction increased from 29 +/- 2 to 31 +/- 4%. This represented a disproportionate rise in glomerular filtration rate over renal plasma flow. Plasma aldosterone and norepinephrine decreased whereas plasma renin activity remained unchanged. In association with these hemodynamic, excretory and endocrine changes, the urinary excretion of cyclic guanosine monophosphate doubled. Placebo had no effect. These results showed that, despite high circulating levels of atrial natriuretic peptide, administration of this hormone in heart failure is associated with potentially beneficial hemodynamic, renal and endocrine effects.

This article has been cited by other articles:

				R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF]

				O. Celik, I. Sahin, N. Celik, S. Hascalik, L. Keskin, H. Ozcan, A. Uckan, and F. Kosar Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study Hum. Reprod., November 1, 2007; 22(11): 2992 - 2998. [Abstract] [Full Text] [PDF]

				M. Schmitt, P. Gunaruwan, N. Payne, J. Taylor, L. Lee, A. J.M. Broadley, A. K. Nightingale, J. R. Cockcroft, A. D. Struthers, J. V. Tyberg, et al. Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 911 - 917. [Abstract] [Full Text]

				T. S. Mir, R. Laux, H. H. Hellwege, B. Liedke, C. Heinze, H. von Buelow, S. Laer, and J. Weil Plasma Concentrations of Aminoterminal Pro Atrial Natriuretic Peptide and Aminoterminal Pro Brain Natriuretic Peptide in Healthy Neonates: Marked and Rapid Increase After Birth Pediatrics, October 1, 2003; 112(4): 896 - 899. [Abstract] [Full Text] [PDF]

				D. R. McClean, H. Ikram, S. Mehta, J. T. Heywood, M. F. Rousseau, A. L. Niederman, R. F. Sequeira, E. Fleck, S. N. Singh, B. Coutu, et al. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects J. Am. Coll. Cardiol., June 19, 2002; 39(12): 2034 - 2041. [Abstract] [Full Text] [PDF]

				G. A. Sagnella Atrial natriuretic peptide mimetics and vasopeptidase inhibitors Cardiovasc Res, August 15, 2001; 51(3): 416 - 428. [Abstract] [Full Text] [PDF]

				H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]

				D. R. McClean, H. Ikram, A. H. Garlick, A. M. Richards, M. G. Nicholls, and I. G. Crozier The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure J. Am. Coll. Cardiol., August 1, 2000; 36(2): 479 - 486. [Abstract] [Full Text] [PDF]

				T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942. [Abstract] [Full Text] [PDF]

				B. L. Abramson, S.-i. Ando, C. F. Notarius, G. A. Rongen, and J. S. Floras Effect of Atrial Natriuretic Peptide on Muscle Sympathetic Activity and Its Reflex Control in Human Heart Failure Circulation, April 13, 1999; 99(14): 1810 - 1815. [Abstract] [Full Text] [PDF]

				L. S. Marcus, D. Hart, M. Packer, M. Yushak, N. Medina, R. S. Danziger, D. F. Heitjan, and S. D. Katz Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Crossover Trial Circulation, December 15, 1996; 94(12): 3184 - 3189. [Abstract] [Full Text]

				R. O. Bonow New Insights Into the Cardiac Natriuretic Peptides Circulation, June 1, 1996; 93(11): 1946 - 1950. [Full Text]

				G. Iervasi, A. Clerico, S. Berti, A. Pilo, A. Biagini, R. Bianchi, and L. Donato Altered Tissue Degradation and Distribution of Atrial Natriuretic Peptide in Patients With Idiopathic Dilated Cardiomyopathy and Its Relationship With Clinical Severity of the Disease and Sodium Handling Circulation, April 1, 1995; 91(7): 2018 - 2027. [Abstract] [Full Text]

				J. G. Motwani, C. C. Lang, G. Cramb, and A. D. Struthers Natriuretic Response to Neutral Endopeptidase Inhibition Is Blunted by Enalapril in Healthy Men Hypertension, April 1, 1995; 25(4): 637 - 642. [Abstract] [Full Text]